^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Max-40279

    i
    Other names: Max-40279, MAX 40279, Max 4, MAX-40279-001, MAX-40279-01, MAX40279
    Company:
    Maxinovel
    Drug class:
    PDGFR inhibitor, FLT3 inhibitor, FGFR1 inhibitor, FGFR2 inhibitor, JAK inhibitor, HPK1 inhibitor
    Related drugs:
    almost2years
    A Phase 2 Study to Evaluate the Safety and Efficacy of Max-40279-01 in Patients With Advanced Gastric Cancer or Gastroesophageal Junction Cancer (clinicaltrials.gov)
    P2, N=30, Recruiting, Maxinovel Pty., Ltd.
    New P2 trial
    |
    FGFR1OP2 (FGFR1 Oncogene Partner 2)
    |
    FGFR1 expression
    |
    Max-40279
    2years
    A Study to Evaluate the Safety and Efficacy of Max-40279 and Toripalimab in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=28, Recruiting, Maxinovel Pty., Ltd.
    New P1 trial • Combination therapy
    |
    FGFR1OP2 (FGFR1 Oncogene Partner 2)
    |
    FGFR1 expression
    |
    Loqtorzi (toripalimab-tpzi) • Max-40279
    over2years
    MAX-40279 in Subjects With Acute Myelogenous Leukemia (AML) (clinicaltrials.gov)
    P1, N=30, Recruiting, Maxinovel Pty., Ltd. | Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Nov 2021 --> Nov 2022
    Clinical • Trial completion date • Trial primary completion date
    |
    FLT3 (Fms-related tyrosine kinase 3) • FGFR (Fibroblast Growth Factor Receptor)
    |
    FLT3 wild-type
    |
    Max-40279
    over2years
    A Clincal Study of Max-40279-01 in Patients With Advanced Colorectal Cancer (clinicaltrials.gov)
    P2, N=130, Not yet recruiting, Maxinovel Pty., Ltd. | Trial completion date: Oct 2022 --> Oct 2023
    Clinical • Trial completion date
    |
    BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability)
    |
    MSI-H/dMMR • BRAF mutation • RAS wild-type
    |
    Stivarga (regorafenib) • Max-40279
    over2years
    A Clincal Study of Max-40279-01 in Patients With Advanced Colorectal Cancer (clinicaltrials.gov)
    P2, N=130, Not yet recruiting, Maxinovel Pty., Ltd.
    Clinical • New P2 trial
    |
    BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability)
    |
    MSI-H/dMMR • BRAF mutation • RAS wild-type
    |
    Stivarga (regorafenib) • Max-40279
    almost3years
    MAX-40279 in Subjects With Acute Myelogenous Leukemia (AML) (clinicaltrials.gov)
    P1, N=30, Recruiting, Maxinovel Pty., Ltd. | Trial completion date: May 2021 --> Dec 2021 | Trial primary completion date: Nov 2020 --> Nov 2021
    Clinical • Trial completion date • Trial primary completion date
    |
    FLT3 (Fms-related tyrosine kinase 3) • FGFR (Fibroblast Growth Factor Receptor)
    |
    Max-40279